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Mantle cell lymphoma (MCL) is a relatively rare subgroup of 
non-Hodgkin’s lymphoma that is characterized by an aggres-
sive and severe disease course with frequent involvement 
of regional lymph nodes and/or early metastasis. Because 
most cases of MCL are diagnosed in the advanced stages, 
clinical data on extranodal or early stage MCL is lacking, and 
MCL that is both extranodal and diagnosed during the early 
stages is even more rare. There have been several case 
reports on primary gastric MCL, which comprise a type of ex-
tranodal MCLs. However, to our knowledge, there have been 
no reports on solitary primary gastric MCL without regional 
lymph node involvement or distant metastasis. Recently, the 
authors experienced an uncommon case of MCL with the 
aforementioned characteristics that was managed with che-
motherapy followed by allogenic stem cell transplantation. 
(Gut Liver 2011;5:527-531)
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INTRODUCTION
Mantle cell lymphoma (MCL) is a unique subgroup of non-
Hodgkin’s lymphoma, which accounts for approximately 6% 
of non-Hodgkin’s lymphoma. MCL is characterized by t(11;14)
(q13;q32) and cyclin D1 overexpression in a vast majority of 
cases. It is also characterized by aggressive disease course with 
many cases being diagnosed in the advanced stages, and fre-
quent involvement of regional lymph nodes and/or early metas-
tasis.
1 In addition to the regional lymph nodes, extranodal sites 
such as gastrointestinal tract are frequently involved. According 
to previous studies, the frequency of extranodal involvement 
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was reported up to 80%, and 15% to 30% of MCL had gastro-
intestinal tract involvement.
2,3 However, solitary and primary 
involvement of extranodal sites is rare, and solitary primary ex-
tranodal MCL diagnosed in the early stage is even rarer. To the 
best of our knowledge, a few cases on primary gastric MCL were 
reported,
4-6 but there had been no documented reports dealing 
with solitary primary gastric MCL without regional lymph node 
involvement or distant metastasis.
Herein, we report the first case of primary gastric MCL which 
was found as solitary lesion in the stomach without any region-
al lymph nodes involvement or distant metastasis.
CASE REPORT
A 48-year-old man presented to the department of gastro-
enterology with epigastric soreness of 8 months’ duration. On 
arrival, his vital signs were stable: blood pressure was 110/70 
mm Hg, pulse rate was 70 beats/min, and body temperature was 
36.8
oC. On physical examination, no mass could be palpated, no 
organ enlargement such as hepatosplenomegaly or lymph node 
enlargement was noted, and neither tenderness nor rebound 
tenderness was present. Initial laboratory findings were as fol-
lows: hemoglobin, 13.0 g/dL; white blood cell count, 5,750/μL 
(45.6%: neutrophils); platelet count, 215,000/μL; blood urea ni-
trogen, 13 mg/dL; creatinine, 1.1 mg/dL; total protein, 6.4 g/dL; 
albumin, 3.4 g/dL; total bilirubin, 0.62 mg/dL; alkaline phos-
phatase, 70 IU/L; alanine aminotransferase, 24 IU/L; aspartate 
aminotransferase, 23 IU/L; gamma glutamyl transferase, 13 IU/
L; lactate dehydrogenase, 388 IU/L; prothrombin time, 13.1 sec 
(INR, 0.98); amylase, 83 IU/L; ESR, 17 mm/hr; CRP, 2.570 mg/L; 
alpha-fetoprotein, 7.1 ng/mL. Hepatitis B surface antigen (HB-
sAg) was positive, and hepatitis B envelope antigen/antibody 528  Gut and Liver, Vol. 5, No. 4, December 2011
(HBeAg/Ab) was positive/negative. Antibody against hepatitis 
B surface antigen (anti-HBs Ab) and antibody against hepati-
tis C (anti-HCV Ab) were all negative. Initial gastrofiberscopic 
examination showed two masses: a 3×3×1.5 cm sized smaller 
crater-like ulcerating mass with central ulceration (1×1 cm) on 
the high-body anterior wall and a 6.5×4.5×2.5 cm sized larger 
swimming goggle shaped ulcerofungating mass with central 
ulceration (2.5×2 cm) on the low-body along the greater curva-
ture (Fig. 1).
The biopsy specimen obtained from the low-body showed 
Fig. 1. Initial gastrofiberscopy shows 
a goggle-shaped ulcerofungating 
mass on the low body along the 
greater curvature (A) and a crater-
like ulcerative mass with bleeding 
on the high-body anterior wall (B).
Fig. 2. Gastric mucosal biopsy from the low body shows diffuse infiltration of medium-sized lymphoid cells with a dispersed chromatin pattern (A, 
H&E stain, ×40; B, ×400).
Fig. 3. Immunohistochemistry with the same specimen from Fig. 2 shows that these cells were diffusely and strongly positive for CD20 (A, ×40) 
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diffuse infiltration of relatively monotonous, medium-sized 
lymphoid cells with dispersed chromatin pattern (Fig. 2). These 
cells were diffusely and strongly positive for CD20 (Fig. 3A), 
CD5, CD43, and cyclin D1 (Fig. 3B), but negative for CD3, CD21, 
CD10, and TdT. Some bcl 6-positive cells were also seen. Most 
cells were positive for Ki-67 (Fig. 4A). Therefore, it could be di-
agnosed as mantle cell lymphoma, blastoid variant. The biopsy 
specimen obtained from the high-body showed focal lymphoid 
infiltration in lamina propria (Fig. 4B). These infiltrates were 
mixture of CD20-positive B cells and CD3-positve T cells. How-
ever, immunostain for cyclin D1 was negative and Ki-67 label-
ing was low. Because the mucosa was intact and the lymphoid 
infiltrates were localized, the biopsy might be obtained from the 
periphery of the ulcerating lesion, representing chonic follicular 
gastritis. Therefore, the possibility of concomitant MCL could 
not be completely ruled out, which might have been due to in-
adequate amount of biopsy specimen.
On endoscopic ultrasonography, the larger swimming goggle 
shaped ulcerofungating mass on the low-body seemed to have 
advanced to the muscularis propria without involvement of 
the serosa (Fig. 5). Abdominal computed tomography (CT) scan 
showed 6.5×2.5 cm sized lobulated enhancing mass with ulcer-
ation in the center, which was located on the low-body. How-
ever, neither definite metastatic lesion nor regional lymph node 
involvement was seen. Colonoscopy, chest CT, bone scan, PET-
CT scan, and bone marrow biopsy were performed for further 
staging work-up but no regional lymph node involvement or 
distant metastasis was found. Conventional cytogenetic analysis 
was also performed with the specimen obtained from the bone 
marrow biopsy; the karyotype was 46,XY and no abnormal 
clone was detected.
Therefore, the patient was diagnosed as stage 1E MCL, and 
was treated with hyperCVAD/MA (cyclophosphamide 300 mg/
m
2, vincristine 2 mg, doxorubicin 50 mg/m
2, dexamethasone 40 
mg; alternated with methotrexate 1 g/m
2 and cytarabine 1 g/m
2 
every 4 weeks or earlier). Follow-up gastrofiberscopy performed 
26 days after third cycle showed that the mass on the high-body 
had been completely resolved leaving behind only a scar, and 
the lesion on the low-body had markedly decreased in size (Fig. 
6A).
Because of prolonged febrile neutropenia after third cycle, 
the dose was reduced by 25% on fourth cycle. The patient 
was scheduled to undergo stem cell transplantation after the 
completion of fifth cycle, but since not enough stem cell could 
be collected for autologous stem cell transplantation, the patient 
underwent allogenic stem cell transplantation instead 69 days 
after fifth cycle. Follow-up gastrofiberscopy performed 40 days 
after allogenic stem cell transplantation showed that the mass 
on the low-body had completely resolved (Fig. 6B). He has com-
pletely recovered afterwards and is currently being followed-
Fig. 4. Immunohistochemistry with the specimen from the low body shows high Ki-67 labeling (A, ×400), but the specimen from the high body, 
which showed lymphoid infiltrates, was negative for cyclin D1 (B, ×40).
Fig. 5. On endoscopic ultrasonography, the mass on the low body 
along the greater curvature shows involvement of the muscularis 
propria (arrows) with an intact serosa.530  Gut and Liver, Vol. 5, No. 4, December 2011
up at the outpatient department without any complaints and 
further complications.
DISCUSSION
MCL is a relatively uncommon and aggressive disorder, being 
incurable in many cases, with median survival of three to four 
years in affected patients.
7
Current World Health Organization guideline suggests that 
morphological examination and immunophenoty ping, with 
demonstration of cyclin D1 protein overexpression and/or 
t(11;14)(q13;q32), are needed for confirmative diagnosis of 
MCL.
8 Morphologically, MCL is generally classifyed into several 
subgroups: classic, small cell, blastoid, marginal zone-like, and 
pleomorphic with some interplay between them. Among these 
subgroups, the blastoid subgroup has the worst prognosis and it 
is composed of variable cell population in size and shape, with 
frequent mitotic figures, oval to irregular nuclear contours, pale 
cytoplasm, and prominent nucleoli.
7,9,10 Immunophenotypically, 
MCL resembles that of a mature B-lymphocyte (CD10
-, CD19
+, 
CD20
+, CD22
+, CD43
+, CD79a
+) with coexpression of the T-cell 
antigen CD5; in contrast to CLL, cells are usually CD23 nega-
tive.
11 In addition, cyclin D1 is almost always overexpressed, 
making it the most important and useful finding for diagnosing 
MCL.
7,9,10 Furthermore, t(11;14)(q13;32) is also seen in most of 
the MCL patients, although some cases of t(11;14)(q13;32) nega-
tive MCL have been reported.
12-15 However, chromosomal study 
with the lymphoma mass was not performed in this patient.
In general, early stage MCL is rare since MCL is diagnosed in 
the advanced stages commonly accompanied by regional lymph 
node involvement, hepatosplenomegaly, bone-marrow involve-
ment, and leukemic spread.
7,9 Primary focus of MCL being other 
than the lymph nodes, i.e., extranodal, is also rare. There have 
been some case reports on primary gastric MCL, but systemic 
involvement
4,5 or regional lymph node involve ment
6 was al-
ways present. There was one case report on solitary primary 
gastric MCL, but gastric MCL was accompanied by synchronous 
early gastric cancer in this case.
16 Primary extranodal MCL 
without regional involvement and/or distant metastasis is even 
rarer, which has been reported by Estrozi et al.;
17 it was primary 
cutaneous blastoid subgroup of MCL in right temporal region 
without regional lymph node involvement and distant metas-
tasis (stage 1E). As far as we know there have been no reports 
on isolated primary gastric MCL in which solitary mass in the 
stomach was the only tumor focus without regional lymph node 
involvement and/or distant metastasis.
Unfortunately there is no established standard treatment 
guideline in patients with MCL. However, the consensus for 
the treatment of MCL is either with myeloablative regimens 
followed by autologous stem cell transplantation after ini-
tial CHOP- (cyclophosphamide, vincristine, doxorubicin, and 
prednisone) or DHAP- (dexamethaso ne, high-dose Ara-C, and 
cisplatin) like induction therapy, or with upfront dose intensifi-
cation (HyperCVAD/MA plus rituximab, a monoclonal antibody 
against the protein CD20).
1 But, since MCL has very aggressive 
disease course and is often diagnosed in the advanced stages, 
the treatment is often unsuccessful. Despite of the initial re-
sponse to chemotherapy, the disease may relapse in many pa-
tients. Therefore, in order to improve the treatment outcomes, 
various intensive chemotherapy combinations, radiotherapy, 
stem cell transplantation, and molecular targeted approaches 
have been tried. Among aforementioned three cases of primary 
gastric MCL, one case reported a 60-year-old man with systemic 
lymph node involvement who was treated with HyperCVAD/
MA plus rituximab followed by stem cell transplantation. He 
had no recurrence for 50 months thereafter.
4 Another case re-
ported a 65-year-old man with synchronous colonic MCL who 
was treated with COP (cyclophosphamide, vincristine, predni-
sone). He also had a complete resolution after six cycles. In the 
last case report, a 74-year-old man with regional lymph node 
involvement suffering from long-standing crohn’s disease was 
treated with rituximab-CHOP. The patient had maintained com-
plete remission state for 18 months after completion of 2 cycles. 
In our case, the patient was very responsive to HyperCVAD/
MA, showing dramatic size reduction of the gastric MCL on 
follow-up gastrofiberscopy resulting in complete remission. But 
unfortunately, he could not undergo autologous stem cell trans-
plantation because not enough stem cells could be collected 
Fig. 6. After the third cycle of che-
motherapy, the huge ulcerofungat-
ing mass on the low-body along 
the greater curvature is markedly 
reduced in size (A). After allogenic 
stem cell transplantation, the lesion 
has completely resolved, leaving be-
hind only a scar (B).Kim CH, et al: Solitary Primary Gastric Mantle Cell Lymphoma  531
for autologous stem cell transplantation. This might have been 
due to bone marrow suppression after intensive chemotherapy. 
Due to the fact that no established standard treatment guideline 
exist, not to mention that for each stages of MCL, many doc-
tors follow similar treatment protocol regardless of the stage at 
diagnosis and thus managing toxicity is another problem MCL 
patents have to face.
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